• Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. 
• The patient’s liver enzymes “recovered rapidly” after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron.
• The patient had elevated liver enzymes, which often indicate damage to cells in the liver, but did not experience any liver-related symptoms or side effects, a Pfizer spokesperson told CNBC.
• The announcement adds to a string of setbacks in the company’s bid to win a slice of the booming market for GLP-1s, which mimic gut hormones to tamp down appetite and regulate blood sugar. 

https://www.cnbc.com/2025/04/14/pfizer-scraps-daily-weight-loss-pill-danuglipron.html